The Heart & Stroke/Richard Lewar Centre of Excellence in Cardiovascular Research (HSRLCE) is pleased to announce an accredited multispecialty educational debate series that explores different points of views with regards to a series of complex questions in the management of cardiovascular and renal complications in patient with or without diabetes.
Program Learning Objectives
Upon completion of this program, participants will be better able to:
- Discuss the cardiorenal protective role of sodium-glucose transport protein 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1-RA) in patients with and without diabetes.
- Compare different treatment sequencing options for SGLT2i and GLP1-RA in type 2 diabetes mellitus (T2DM), as well as in chronic kidney disease and heart failure populations with or without type 2 diabetes, based on recently published data.
There are four debate topics:
- Be it resolved that the first agent initiated in all patients with type 2 diabetes should be an SGLT2i/GLP1-RA in place of metformin.
- Be it resolved that in patients with HF (with or without T2DM) an SGLT2i should be prioritized over an ARNi.
- Be it resolved that a GLP1-RA should be prioritized over a SGLT2i for people with T2DM and ASCVD.
- Be it resolved that in patients with albuminuria, and low-normal blood pressure (with or without T2DM), initiating an SGLT2i over an ACE/ARB will provide more nephroprotection.
Upcoming Debate Sessions:
April 28, 2021 – 8 to 9:30 pm EST
- Topics 1 and 4
- Debaters: Alice Y. Y. Cheng, MD, FRCPC (Endocrinologist) and Louis Girard, MD, MBT, FRCPC (Nephrologist)
- Moderator: Sara Stafford, MD
- Register to attend: https://diabeteslearningonline.com/?mID=139
This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, approved by Continuing Professional Development, Temerty Faculty of Medicine, University of Toronto, for a maximum of 1.5 credits.
This program was co-developed and planned with the HSRLCE to achieve scientific integrity, objectivity and balance, with an unrestricted grant from the Boehringer Ingelheim and Eli Lilly Canada Alliance in Diabetes.